3 terminated, 2 completed, 1 recruiting, 1 unknown. 8 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Terminated 3, Completed 2, Recruiting 1, Unknown 1, Withdrawn 1 |
| Phase 3 | 3 | Completed 2, Withdrawn 1 |
Follow Chlorpheniramine: new trials by email Literature Review of Chlorpheniramine trials Research Report on Chlorpheniramine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-III Chlorpheniramine Maleate 0.4% Nasal Spray, Placebo - COVID-19, Symptoms and Signs | Phase 2 / Phase 3 | Completed | Dr. Ferrer BioPharma | 157 | 2022-07-27 | 2023-06-02 |
| Chlorpheniramine Nasal Spray to Accelerate COVID-19 Clinical Recovery in an Outpatient Setting: ACCROS-I Chlorpheniramine Maleate 1% Nasal Spray, Placebo - COVID-19, Symptoms and Signs | Phase 2 / Phase 3 | Completed | Dr. Ferrer BioPharma | 101 | 2021-12-07 | 2023-03-23 |
| Efficacy of Placebo Versus Chlorpheniramine for the Prevention of Allergic Transfusion Reactions. Placebo, Chlorpheniramine - Allergic Transfusion Reaction | Phase 2 | Recruiting | Institute of Hematology & Blood Diseases Hospital, China | 6642 | 2021-01-01 | 2026-11-12 |
| Chlorpheniramine Maleate Nasal Spray for Chronic Rhinitis CPM, Placebo - Allergic Rhinitis, Nasal Congestion | Phase 2 / Phase 3 | Withdrawn | Larkin Community Hospital | 2019-07-30 | 2023-10-16 | |
| Clinical Trial of the Safety and Efficacy of SP160412 in the Temporary Relief of Mild to Moderate Sunburn SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg, 2 capsules Ibuprofen and 1 placebo, capsule Chlorpheniramine 4mg and 1 Placebo - Sunburn | Phase 2 | Terminated | Sephoris Pharmaceuticals LLC | 80 | 2018-01-15 | 2019-09-27 |
| Exploratory Study for Allergy Relief Onset Chlorpheniramine maleate (BAY X002134), Placebo - Rhinitis, Allergic | Phase 2 | Terminated | Bayer | 1 | 2016-05-07 | 2018-12-12 |
| A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection ARC-520, Placebo, entecavir - Hepatitis B, Chronic | Phase 2 | Terminated | Arrowhead Pharmaceuticals | 58 | 2014-03-01 | 2026-01-13 |
| StahistRx Phase 2, Five-arm, Parallel Group, Active vs Active, Double-blind Study PSE 120 mg, CM 8 mg, Atr 0.36 mg, PSE 120 mg, CM 8 mg, Atr 0.24 mg, PSE 120 mg, CM 8 mg, Atr 0.12 mg - Rhinitis, Seasonal, Allergic | Phase 2 | Unknown | Magna Pharmaceuticals, Inc. | 125 | 2014-03-01 | 2014-05-30 |
COVID-19 (2) · Coronavirus Infections (2) · Rhinitis, Allergic (2) · Signs and Symptoms (2) · Hepatitis (1) · Hepatitis B, Chronic (1) · Nasal Obstruction (1) · Rhinitis (1) · Rhinitis, Allergic, Seasonal (1) · Sunburn (1)
Dr. Ferrer BioPharma (2) · Arrowhead Pharmaceuticals (1) · Bayer (1) · Institute of Hematology & Blood Diseases Hospital, China (1) · Larkin Community Hospital (1) · Magna Pharmaceuticals, Inc. (1) · Sephoris Pharmaceuticals LLC (1)
United States (3) · Honduras (2) · China (1) · Hong Kong (1) · Mauritius (1)
Bruce Given, MD (1) · Gitanjali Petkar, M.D (1) · Marcos A Sanchez-Gonzalez (1) · Stephen J Pollard, MD (1)